Preparation and application of patient-derived xenograft mice model of colorectal cancer.

• DOI: 10.22038/ijbms.2022.67445.14780
• Publication Date: 2023-02-01
• Authors: Yutao Zhang; Yongming Yang; Likun Zan; Jing Wang; Lei Yan; Lili Zhao; Lixia Chen; Yanfeng Xi; Wenqi Bai; Xihua Yang
• Keywords: Carcinoembryonic antigen; Primary tumor

Patient-derived xenograft (PDX) model becomes a more and important tool for tumor research. This study aimed to establish colorectal cancer PDX verify its applicability.Fresh human tissue was surgically removed subcutaneously inoculated into immunodeficient mice the model. Hematoxylin eosin (HE) staining immunohistochemical were used evaluate The successful selected efficacy of capecitabine in treating cancer.HE showed that could preserve histological characteristics primary tumor. Immunohistochemistry α-fetoprotein (AFP), carcinoembryonic antigen (CEA), E-cadherin strongly positively expressed tissues, with high degree similarity. Capecitabine significantly inhibited growth reduced expression AFP CEA proteins tissues (all Ps<0.05).We successfully established model, retain biological Using this we revealed at dose 300-400 mg/kg can effectively treat cancer, no significant difference toxicity found among different groups. current work provides feasible framework establishing validating better facilitate evaluation drug safety.